Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Decker

Showing results (461-470 of 475) with videos related to

Pageof 48
Sort By:
Journal of Virology|September 15, 2006
Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern AfricaMing Li, Jesus F Salazar-Gonzalez, Cynthia A Derdeyn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancerKevin C Conlon, Enrico Lugli, Hugh C Welles, et al.
Plos Pathogens|June 14, 2012
Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escapeKatharine J Bar, Chun-yen Tsao, Shilpa S Iyer, et al.
American Journal of Respiratory and Critical Care Medicine|August 15, 2025
Active Antigen-Specific Adaptive Immune Responses Are Shared among Patients with Progressive Fibrotic Interstitial Lung DiseaseTania E Velez, Young Me Yoon, Vaibhav Upadhyay, et al.
Plos Pathogens|June 14, 2012
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7Nicholas F Parrish, Craig B Wilen, Lauren B Banks, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 2, 2013
Phenotypic properties of transmitted founder HIV-1Nicholas F Parrish, Feng Gao, Hui Li, et al.
Bioorganic & Medicinal Chemistry Letters|November 23, 2024
Discovery of novel cyclopentane carboxylic acids as potent and selective inhibitors of Na<sub>V</sub>1.7Shaoyi Sun, Sultan Chowdhury, Ivan Hemeon, et al.
The Journal of Experimental Medicine|June 3, 2009
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infectionJesus F Salazar-Gonzalez, Maria G Salazar, Brandon F Keele, et al.
Mbio|April 23, 2015
Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillasHannah J Barbian, Julie M Decker, Frederic Bibollet-Ruche, et al.
Nature|February 25, 2015
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challengesMatthew R Gardner, Lisa M Kattenhorn, Hema R Kondur, et al.
Pageof 48

Showing results (461-470 of 475) with videos related to

Sort By:
Pageof 48
Journal of Virology|September 15, 2006
Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern AfricaMing Li, Jesus F Salazar-Gonzalez, Cynthia A Derdeyn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancerKevin C Conlon, Enrico Lugli, Hugh C Welles, et al.
Plos Pathogens|June 14, 2012
Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escapeKatharine J Bar, Chun-yen Tsao, Shilpa S Iyer, et al.
American Journal of Respiratory and Critical Care Medicine|August 15, 2025
Active Antigen-Specific Adaptive Immune Responses Are Shared among Patients with Progressive Fibrotic Interstitial Lung DiseaseTania E Velez, Young Me Yoon, Vaibhav Upadhyay, et al.
Plos Pathogens|June 14, 2012
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7Nicholas F Parrish, Craig B Wilen, Lauren B Banks, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 2, 2013
Phenotypic properties of transmitted founder HIV-1Nicholas F Parrish, Feng Gao, Hui Li, et al.
Bioorganic & Medicinal Chemistry Letters|November 23, 2024
Discovery of novel cyclopentane carboxylic acids as potent and selective inhibitors of Na<sub>V</sub>1.7Shaoyi Sun, Sultan Chowdhury, Ivan Hemeon, et al.
The Journal of Experimental Medicine|June 3, 2009
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infectionJesus F Salazar-Gonzalez, Maria G Salazar, Brandon F Keele, et al.
Mbio|April 23, 2015
Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillasHannah J Barbian, Julie M Decker, Frederic Bibollet-Ruche, et al.
Nature|February 25, 2015
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challengesMatthew R Gardner, Lisa M Kattenhorn, Hema R Kondur, et al.
Pageof 48